Cunningham, Evan B ×
2 results
  1. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

    Cunningham, Evan B, Hajarizadeh, Behzad, Dalgard, Olav, Amin, Janaki, Hellard, Margaret, Foster, Graham R, Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert, Swan, Tracy, Marks, Philippa S, Quiene, Sophie, Applegate, Tanya L, Weltman, Martin, Shaw, David, Dunlop, Adrian, Bruneau, Julie, Midgard, Håvard, Bourgeois, Stefan, Thurnheer, Maria Christine, Dore, Gregory J, Grebely, Jason, Shaw, Ineke, Siriragavan, Sharmila, Horschik, Tina, Sharma, Shawn, Eevers, Anita, Andreassen, Jessica, Melkeraaen, Ingunn, Widder, Nicole, Lesneuck, Kristof, Kotsoros, Barbara, Hazelwood, Susan, Holland, Rohan, Axten, David, Von Bibra, Sally, Powis, Jeff, Mason, Kate, Ryder, Stephen, Jack, Kate, Scheidegger, Claude, Huber, Christine, Ferguson, Catherine, Staehelin, Cornelia, Lacalamita, Melanie, Fragomeli, Vincenzo, Sevehon, Alison ()
  2. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

    Grebely, Jason, Dalgard, Olav, Cunningham, Evan B, Hajarizadeh, Behzad, Foster, Graham R, Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert, Swan, Tracy, Amin, Janaki, Marks, Philippa S, Quiene, Sophie, Applegate, Tanya L, Weltman, Martin, Shaw, David, Dunlop, Adrian, Hellard, Margaret, Bruneau, Julie, Midgard, Håvard, Bourgeois, Stefan, Staehelin, Cornelia, Dore, Gregory J ()